KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $190.0 million.

  • Bristol Myers Squibb's Current Deferred Revenue fell 1949.15% to $190.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.0 million, marking a year-over-year decrease of 1949.15%. This contributed to the annual value of $222.0 million for FY2024, which is 1897.81% down from last year.
  • As of Q3 2025, Bristol Myers Squibb's Current Deferred Revenue stood at $190.0 million, which was down 1949.15% from $203.0 million recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's Current Deferred Revenue peaked at $367.0 million during Q1 2021, and registered a low of $190.0 million during Q3 2025.
  • Its 5-year average for Current Deferred Revenue is $283.5 million, with a median of $289.0 million in 2022.
  • In the last 5 years, Bristol Myers Squibb's Current Deferred Revenue tumbled by 368.1% in 2023 and then plummeted by 1949.15% in 2025.
  • Bristol Myers Squibb's Current Deferred Revenue (Quarter) stood at $330.0 million in 2021, then fell by 12.42% to $289.0 million in 2022, then dropped by 5.19% to $274.0 million in 2023, then decreased by 18.98% to $222.0 million in 2024, then decreased by 14.41% to $190.0 million in 2025.
  • Its Current Deferred Revenue was $190.0 million in Q3 2025, compared to $203.0 million in Q2 2025 and $217.0 million in Q1 2025.